Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

181. Insulin glargine (Abasaglar®)

Insulin glargine (Abasaglar®) Insulin glargine (Abasaglar®) Insulin glargine (Abasaglar®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin glargine (Abasaglar®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines (...) Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2307. 2015 Authors' conclusions Insulin glargine (Abasaglar®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Insulin glargine (Abasaglar®) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus®), the reference product. Insulin glargine (Abasaglar

Health Technology Assessment (HTA) Database.2016

182. The Long Story Short: Optimizing choice and use of insulin needles

The Long Story Short: Optimizing choice and use of insulin needles image/jpeg

RxFiles2016

184. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. 26624824 2015 12 02 2016 01 04 2017 04 27 1538-3598 314 21 2015 Dec 01 JAMA JAMA Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. 2241-50 10.1001/jama.2015.16174 Previous studies assessing the effect of metformin on glycemic control in adolescents with type (...) 1 diabetes have produced inconclusive results. To assess the efficacy and safety of metformin as an adjunct to insulin in treating overweight adolescents with type 1 diabetes. Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled randomized clinical trial involving 140 adolescents aged 12.1 to 19.6 years (mean [SD] 15.3 [1.7] years) with mean type 1 diabetes duration 7.0 (3.3) years, mean body mass index (BMI) 94th (4) percentile, mean total daily insulin 1.1 (0.2) U/kg, and mean

JAMA2015

185. Insulin glargine (Abasaglar) - for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above

Insulin glargine (Abasaglar) - for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above %PDF-1.5 %���� 52 0 obj > endobj 70 0 obj >/Filter/FlateDecode/ID[ ]/Index[52 36]/Info 51 0 R/Length 90/Prev 199745/Root 53 0 R/Size 88/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$���" �� $�� 5��~w�X���Xv@�;�M H0� �� ��8������0H���J��m ��8 endstream endobj startxref 0 %%EOF 87 0 obj >stream h�b`````jd_�0�F fa�h@�b�!���.�K ��.�L`*f�� �@C��P�� �I�.@Mb��b"��Y, ���QF1�g3

All Wales Medicines Strategy Group2015

186. Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus

Insulin degludec/liraglutide (Xultophy) - for the treatment of adults with type 2 diabetes mellitus %PDF-1.5 %���� 76 0 obj > endobj 97 0 obj >/Filter/FlateDecode/ID[ ]/Index[76 44]/Info 75 0 R/Length 97/Prev 223751/Root 77 0 R/Size 120/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$��X�@��0��$�ׂA�$X�A,^��*�+���U !@�� ������@,�Q[y�n��10Қ�ϸ� @�.5S endstream endobj startxref 0 %%EOF 119 0 obj >stream h�b```c``������s�A���X���v700� �%EK1t4�u4������9(H �X$���!�ss$�z��w�v2Lm���p�`�P%�rޮ� ��8�� >/Metadata 10

All Wales Medicines Strategy Group2015

187. Insulin degludec/liraglutide (Xultophy®)

Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin degludec/liraglutide (Xultophy®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2544. 2015 Authors' conclusions Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide

Health Technology Assessment (HTA) Database.2015

188. [Insulin infusion pumps for diabetic patients]

[Insulin infusion pumps for diabetic patients] Bombas de infusión de insulina en pacientes diabéticos [Insulin infusion pumps for diabetic patients] Bombas de infusión de insulina en pacientes diabéticos [Insulin infusion pumps for diabetic patients] Mengarelli C, Pichon-Riviere A, Rey-Ares L, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Mengarelli C, Pichon-Riviere A, Rey-Ares L, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A. Bombas de infusión de insulina en pacientes diabéticos. [Insulin infusion pumps for diabetic patients] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 424. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and coverage

Health Technology Assessment (HTA) Database.2015

189. Guide to Starting and Adjusting Insulin for Type 2 Diabetes

Guide to Starting and Adjusting Insulin for Type 2 Diabetes Guide to Starting and Adjusting Insulin for Type 2 Diabetes | CADTH.ca Find the information you need Guide to Starting and Adjusting Insulin for Type 2 Diabetes Guide to Starting and Adjusting Insulin for Type 2 Diabetes Published on: July 16, 2012 Result type: Report Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes , ©2008 International Diabetes Center, Minneapolis, MN. All rights reserved. Many people (...) with type 2 diabetes need insulin therapy. A variety of regimens are available. Here are some tips when discussing insulin therapy: 1 Discuss insulin early to change negative perceptions (e.g., how diabetes changes over time; insulin therapy as a normal part of treatment progression). To encourage patient buy-in, it may be more strategic initially to begin with a regimen that will be the most acceptable to the patient even if it may not be the clinician's first choice (e.g., pre-mixed instead of basal-bolus

CADTH - Optimal Use2015

190. Insulin glargine (Basaglar)

Insulin glargine (Basaglar) Insulin glargine | CADTH.ca Find the information you need Insulin glargine Insulin glargine Last Updated: Result type: Reports Project Number: SE0451-000 Product Line: Generic Name: Insulin glargine Brand Name: Basaglar Manufacturer: Eli Lilly Canada Inc. Indications: Diabetes mellitus, Type 1 & 2 Submission Type: New Project Status: Complete Date Recommendation Issued: April 14, 2016 Recommendation Type: List with clinical criteria and/or conditions Tags biosimilar

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

191. Efficacy and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes

Efficacy and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes 26486192 2015 11 25 2016 06 27 2015 11 25 1935-5548 38 12 2015 Dec Diabetes care Diabetes Care Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. 2258-65 10.2337/dc15-1730 This study assessed the efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor (...) , as add-on to insulin in adults with type 1 diabetes. This 18-week, double-blind, phase 2 study randomized 351 patients (HbA1c 7.0-9.0% [53-75 mmol/mol]) on multiple daily insulin injections or continuous subcutaneous insulin infusion to canagliflozin 100 or 300 mg or placebo. The primary end point was the proportion of patients achieving at week 18 both HbA1c reduction from baseline of ≥0.4% (≥4.4 mmol/mol) and no increase in body weight. Other end points included changes in HbA1c, body weight

EvidenceUpdates2015

192. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial 26179619 2015 10 21 2016 07 28 2017 02 20 1463-1326 17 11 2015 Nov Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. 1056-64 (...) 10.1111/dom.12539 To confirm the superiority, compared with placebo, of adding liraglutide to pre-existing basal insulin analogue ± metformin in adults with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)]. In this 26-week, double-blind, parallel-group study, conducted in clinics or hospitals, 451 subjects were randomized 1 : 1 to once-daily liraglutide 1.8 mg (dose escalated from 0.6 and 1.2 mg/day, respectively, for 1 week each; n = 226) or placebo (n

EvidenceUpdates2015

194. [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]

[Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a (...) Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und

Health Technology Assessment (HTA) Database.2015

195. [Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus]

[Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus] Kontinuierliche interstitielle glukosemessung (CGM) mit real-time-messgeräten bei insulinpflichtigem diabetes mellitus [Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus] Kontinuierliche interstitielle glukosemessung (CGM) mit real-time-messgeräten bei insulinpflichtigem diabetes mellitus [Continuous (...) interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Kontinuierliche interstitielle glukosemessung (CGM) mit real-time-messgeräten bei insulinpflichtigem diabetes mellitus. [Continuous interstitial glucose monitoring (CGM

Health Technology Assessment (HTA) Database.2015

196. Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness

Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Epinephrine versus Glucagon for the Management of Severe (...) Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Published on: September 30, 2015 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of epinephrine compared with glucagon for the management of severe hypoglycemia in insulin-dependent patients? What is the cost-effectiveness of epinephrine compared with glucagon for the management of severe hypoglycemia in insulin-dependent patients? Key Message

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

198. Insulin glargine (Toujeo) - Treatment of type 1 or type 2 diabetes mellitus

Insulin glargine (Toujeo) - Treatment of type 1 or type 2 diabetes mellitus Published 07 September 2015 Product Update: insulin glargine 300 units/mL solution for injection in a pre-filled pen (Toujeo ® ) SMC No. (1078/15) Sanofi 10 July 2015 (Issued 7 August 2015) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE (...) : following an abbreviated submission Insulin glargine (Toujeo ® ) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above. SMC restriction: Its use should be targeted on patients with Type I diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins

Scottish Medicines Consortium2015

200. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial 26180109 2015 11 25 2016 06 27 2015 11 25 1935-5548 38 12 2015 Dec Diabetes care Diabetes Care Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial. 2266-73 10.2337/dc15-0075 To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 diabetes. This open-label (...) noninferiority trial compared the change in HbA1c from baseline to week 24 of prandial TI (n = 174) with that of subcutaneous aspart (n = 171), both with basal insulin, in patients with type 1 diabetes and HbA1c 7.5-10.0% (56.8-86.0 mmol/mol). Mean change in HbA1c in TI patients (-0.21% [-2.3 mmol/mol]) from baseline (7.94% [63.3 mmol/mol]) was noninferior to that in aspart patients (-0.40% [-4.4 mmol/mol]) from baseline (7.92% [63.1 mmol/mol]). The between-group difference was 0.19% (2.1 mmol/mol) (95% CI

EvidenceUpdates2015